Lewis J. Smith, MD
Smith L.; Newer Asthma Therapies. Ann Intern Med. 1999;130:531-532. doi: 10.7326/0003-4819-130-6-199903160-00018
Download citation file:
Published: Ann Intern Med. 1999;130(6):531-532.
For more than 30 years, the medications available for treating asthma have included β-agonists (such as albuterol), phosphodiesterase inhibitors (such as theophylline), corticosteroids (such as prednisone and beclomethasone), and the so-called antiallergic compounds (such as cromolyn). In the past decade, newer drugs of the same type but with improved characteristics, such as greater specificity and longer duration of action (β2-agonists) and reduced systemic bioavailability (inhaled corticosteroids) have become available and are widely used. Rigorous clinical trials of these newer preparations have resulted in a better appreciation of their efficacy, potential toxicity, and appropriate use. At the same time, morbidity and mortality caused by asthma have increased (1, 2). Although multiple theories have been proposed to explain this phenomenon, none so far has proven adequate.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Pulmonary/Critical Care, Asthma.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only